Detection of growth hormone doping by gene expression profiling of peripheral blood.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Their objective was to evaluate gene expression profiling in peripheral blood leukocytes in-vivo as a test for GH doping in humans.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Blood was collected at baseline and at 8 wk.

RNA was extracted from the white cell fraction.

Microarray analysis was undertaken using Agilent 44K G4112F arrays using a two-color design.

Quantitative RT-PCR using TaqMan gene expression assays was performed for validation of selected differentially expressed genes.

What Was Measured

Topics PubMed links to this paper include Doping in Sports, Gene Expression, Gene Expression Profiling, Human Growth Hormone, Insulin-Like Growth Factor I, Oligonucleotide Array Sequence Analysis and RNA.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.